CytomX Therapeutics to Receive $5 Million Milestone Payment from Regeneron
CytomX Therapeutics (CTMX) has announced it will receive a $5 million milestone payment from Regeneron Pharmaceuticals (REGN). This payment follows the successful achievement of a preclinical development milestone within their existing collaborative partnership focused on cancer drug discovery. The news triggered a positive market reaction, with CytomX shares rising 4.6% in extended trading following the announcement. The capital infusion provides additional non-dilutive funding to support CytomX's ongoing research and development efforts.
